Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US

References

• Alzheimer’s Association. 2014 Alzheimer’s Disease Facts and Figures. Alzheimer's & Dementia 2014;10. Available at: https://www.alz.org/downloads/Facts_Figures_2014.pdf
   Google Scholar
• Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80:1778-83
   PubMed Web of Science ®Google Scholar
• Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 2010;22:346-72
   PubMed Web of Science ®Google Scholar
• Karttunen K, Karppi P, Hiltunen A, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. Int J Geriatr Psychiatry 2011;26:473-82
   PubMed Web of Science ®Google Scholar
• California Workgroup on Guidelines for Alzheimer’s Disease Management, State of California, Department of Public Health. Guideline for Alzheimer's Disease Management. Final report, 2008. Available at: http://www.alz.org/socal/images/professional_GuidelineFullReport.pdf
   Google Scholar
• Alzheimer's Disease Program, Chronic Disease Branch Division for Disease Control and Prevention Services, Texas Department of State Health Services. Clinical best practices for early detection, diagnosis, and pharmaceutical and non-pharmaceutical treatment of persons with Alzheimer's Disease. Publication No 44-14023. February 2013. Available at: http://dshs.state.tx.us/alzheimers/pdf/Early-Detection-Final.doc
   Google Scholar
• Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement 2013;9:326-331
   PubMed Web of Science ®Google Scholar
• Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63
   PubMed Web of Science ®Google Scholar
• Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open 2012;2:e000917
   Web of Science ®Google Scholar
• Green C. Modelling disease progression in Alzheimer’s disease. A review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics 2007;25:735-50
   PubMed Web of Science ®Google Scholar
• Pouryamout L, Dams J, Wasem J, et al. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs 2012;72:789-802
   PubMed Web of Science ®Google Scholar
• Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ 2014;15:791-800
   PubMed Web of Science ®Google Scholar
• Lachaine J, Beauchemin C, Legault M, et al. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatry 2011;56:596-604
   PubMed Web of Science ®Google Scholar
• Pfeil AM, Kressig RW, Szucs TD. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss Med Wkly 2012;142:w13676
   PubMed Web of Science ®Google Scholar
• Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 2007;23:1187-97
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs 2013;27:469-78
   PubMed Web of Science ®Google Scholar
• Hartz S, Getsios D, Tao S, et al. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation. BMC eurology 2012;12
   Google Scholar
• Getsios D, Blume S, Ishak KJ, et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics 2010;28:411-27
   PubMed Web of Science ®Google Scholar
• Bergh S, Selbaek G, Engedal K. Reliability and validity of the Norwegian version of the Severe Impairment Battery (SIB). Int J Geriatr Psychiatry 2008;23:896-902
   PubMed Web of Science ®Google Scholar
• Tun SM, Murman DL, Long HL, et al. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry 2007;15:314-27
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables, 2008. National vital statistics reports; vol 61 no 3. Hyattsville, MD: National Center for Health Statistics, 2012. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_03.pdf
   Google Scholar
• Fitzpatrick AL, Kuller LH, Lopez OL, et al. Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci 2005;229–230:43-9
   PubMed Web of Science ®Google Scholar
• Lachaine J, Beauchemin C, Crochard A, et al. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Regie de l'Assurance Maladie du Quebec database. Can J Psychiatry 2013;58:195-200
   PubMed Web of Science ®Google Scholar
• Red Book Online. Truven Health Analytics. Available at: www.redbook.com Accessed on: August 27, 2013
   Google Scholar
• SDI Vector One Payer, Total prescription utilization for the Alzheimer’s class of the last four calendar quarters ending June 2013. Available at: http://www.imshealth.com
   Google Scholar
• Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008;179:438-46
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Brinck P, Bergvall N, et al. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. Alzheimers Dement 2011;7:318-27
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics 2000;17:351-60
   PubMed Web of Science ®Google Scholar
• Bell CM, Araki SS, Neumann PJ. The association between caregiver burden and caregiver health-related quality of life in Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:129-36
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer Price Index, 2013, Area: US city average, Item: medical care, Base period: 1982–84, Years: 1995–2013. Available at: http://www.bls.gov/cpi/. Accessed on June 3, 2013
   Google Scholar
• Leon J, Neumann PJ, Hermann RC, et al. Health-related quality-of-life and service utilization in Alzheimer's disease: a cross-sectional study. Am J Alzheimer's Dis Other Demen 2000;15:94-108
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. REcommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. 2013 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia 2013;9 . Available at: https://www.alz.org/downloads/facts_figures_2013.pdf
   Google Scholar
• Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33
   PubMed Web of Science ®Google Scholar